Molecular Oncology

Papers
(The H4-Index of Molecular Oncology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
132
Issue Information124
123
Issue Information100
Corrigendum to: Small proline‐rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage‐induced apoptosis81
Erratum to: Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors80
Lysosome‐dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer77
PoDCall: a robust tool for automated droplet classification in DNA‐methylation droplet digital PCR75
71
Precision Cancer Medicine 2.0—Oncology in the postgenomic era69
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer65
Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 + mononuc54
Correction to “Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition”51
Unraveling the metastasis‐preventing effect of miR‐200c in vitro and in vivo48
Evaluation of two new highly multiplexed PCR assays as an alternative to next‐generation sequencing for IDH1/2 mutation detection47
Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF146
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 442
Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1 38
Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy37
Ovarian cancer relies on the PDGFRβ –fibronectin axis for tumorsphere formation and metastatic spread36
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer35
Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for 34
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐ CD 73/anti‐ 34
Correction to “SPT6 recruits SND1 to co‐activate human telomerase reverse transcriptase to promote colon cancer progression”31
An arms‐race against resistance: leukemic stem cells and lineage plasticity31
Gene signature predicting recurrence in oral squamous cell carcinoma is characterized by increased oxidative phosphorylation30
Development of an optimized, non‐stem cell line for intranasal delivery of therapeutic cargo to the central nervous system30
Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with 30
Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities29
Unraveling LINE ‐1 retrotransposition in head and neck squamous cell carcinoma29
Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma29
NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy29
Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment29
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity29
0.16016316413879